Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-19T12:21:35.136Z Has data issue: false hasContentIssue false

9 - Therapeutic decision making in BMT/SCT for Hodgkin lymphoma

Published online by Cambridge University Press:  05 August 2013

By
Reinhold Munker ,
Hillard M. Lazarus  and
Kerry Atkinson
Edited by
Reinhold Munker ,
Gerhard C. Hildebrandt ,
Hillard M. Lazarus  and
Kerry Atkinson
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Gerhard C. Hildebrandt
Affiliation:
University of Utah
Hillard M. Lazarus
Affiliation:
Ireland Cancer Center, Case Western Reserve University Hospital, Cleveland
Kerry Atkinson
Affiliation:
University of Queensland
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The BMT Data Book
Including Cellular Therapy
 , pp. 113 - 121
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Colpo, A, Hochberg, E, & Chen, YB. 2012. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma. Oncologist 17: 80–90.CrossRefGoogle ScholarPubMed
Connors, JM. 2005. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 23: 6400–6408.CrossRefGoogle ScholarPubMed
Hasenclever, D & Diehl, V. 1998. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339: 1506–1514.CrossRefGoogle ScholarPubMed
Kuruvilla, J, Keating, A, & Crump, M. 2011. How I treat relapsed and refractory Hodgkin lymphoma. Blood 117: 4208–4217.CrossRefGoogle Scholar
Kuruvilla, J, Nagy, T, Pintilie, M, et al. 2006. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106: 353–360.CrossRefGoogle ScholarPubMed
Lazarus, HM, Rowlings, PA, Zhang, MJ, et al. 1999. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 17: 534–545.CrossRefGoogle ScholarPubMed
Milpied, N, Fielding, AK, Pearce, RM, et al. 1996. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J Clin Oncol 14: 572–578.CrossRefGoogle Scholar
Porter, DL, Stadtmauer, EA, & Lazarus, HM. 2003. “GVHD”: graft-versus-host disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning. Bone Marrow Transplant 31: 739–746.CrossRefGoogle ScholarPubMed
Sarina, B, Castagna, L, Farina, L, et al. 2011. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 115: 3671–3677.CrossRefGoogle Scholar
Sureda, A, Constans, M, Iriondo, A, et al. 2005. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 16: 625–633.CrossRefGoogle ScholarPubMed
Tubiana, M, Henry-Amar, M, Cardé, P, et al. 1989. Toward comprehensive management tailored to prognostic factors of clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–87. Blood 73: 47–56.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×